mixngo the disruptive technology, page-2

Hi Twinvest,
I do find the new prostate cancer cell detection test of Quanterix also very interesting, particularly since this array can most likely be extended to Alzheimer's and Crohn disease detection.
As far back as 2008, former ( about current CEO see comment below ) CEO Nick Naclerio had told BioArray News that Quanterix's single molecule array, or SiMoA, platform is well suited for molecular diagnostics, and that the company is already engaged in its first clinical collaborations with partners.

3 years do sound like a fair, approximate timeframe to run those clinical trials up to the point at which it would make feasable sense to incorpoate our glue.

Therefore your speculation has to much go on.


As I have recently stated my speculation of Siemens having strong motivations to implement our technology, it is of interest that the current CEO of Quanterix, Dr David Akrongly, was the former Senior Vice President in Siemens' Healthcare Diagnostics Division, where he was in charge of the Molecular Diagnostics business unit.